Artificial intelligence is a double-edged sword when it comes to cybersecurity. It is giving defenders new ways to sift through vast amounts of telemetry, identify anomalous behavior and automate routine work. But it is also giving attackers the ability to discover vulnerabilities faster, build more convincing social engineering campaigns, and execute multistage intrusions at a scale that would have required large, well-resourced teams only a few years ago.
Advanced Micro Devices Inc.’s Advancing AI 2026 keynote this week was Chief Executive Lisa Su’s bid to redefine the company from a “graphics processing unit alternative” to a full-stack artificial intelligence infrastructure vendor and to make this the year the central processing unit officially rebounds as a first-class AI platform. The message from Su was ambitious and often compelling, but it also sharpened the competitive contrast with Nvidia Corp. and Intel Corp., raising as many questions as it answered.
Neocloud provider QumulusAI said today that it will starting trading Thursday as a publicly traded company on Nasdaq under the ticker symbol QMLS via a direct listing. For those unfamiliar with the process, the typical initial public offering takes time and requires an investment banker, whereas a direct listing does not create new shares. Instead, existing shareholders sell their shares to the public without an underwriter.
Couchbase Inc. is trying to solve one of the hardest problems in enterprise artificial intelligence today: turning brittle, chat-style pilots into production-grade agents capable of remembering, reasoning and acting on live operational data. With the launch of its AI Data Plane, the company is betting that the real bottleneck for “agentic” AI isn’t the model — it’s the underlying data architecture.
Artificial intelligence played a prominent role at this week’s Bio International Convention in San Diego, the largest biotech event with vendors spanning the full ecosystem of companies in this industry. Today in a special address, Kimberly Powell (pictured), vice president and general manager of healthcare and life sciences at Nvidia Corp., made the case that agentic AI is about to do for biotech what it just did for software — and the company’s BioNeMo is the stack that turns generic large language models into working “AI scientists” that are both faster and cheaper to run.